Designing group sequential randomized clinical trials with time to event end points using a R function

Computer Methods and Programs in Biomedicine

Volumn 108, Issue 1, 2012, Pages 113-128

  Filleron, Thomas ^a   Gal, Jocelyn ^b   Kramar, Andrew ^c  

^a INSTITUT CLAUDIUS REGAUD   (France)

^b CENTRE ANTOINE LACASSAGNE   (France)

^c CENTRE OSCAR LAMBRET   (France)

Author keywords

Group sequential; Non inferiority; R function; Randomized clinical trial; Sample size; Superiority; Time to event endpoint

Indexed keywords

GROUP SEQUENTIAL; NON-INFERIORITY; R-FUNCTIONS; RANDOMIZED CLINICAL TRIALS; SAMPLE SIZES; SUPERIORITY; TIME TO EVENT ENDPOINT;

DESIGN; EXPERIMENTS; MEDICAL APPLICATIONS;

SAMPLING;

ARTICLE; COMPUTER PROGRAM; CONTROLLED STUDY; METHODOLOGY; R FUNCTION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAMPLE SIZE;

ENDPOINT DETERMINATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SOFTWARE;

EID: 84865804431     PISSN: 01692607     EISSN: 18727565     Source Type: Journal    
DOI: 10.1016/j.cmpb.2012.02.002     Document Type: Article

References (35)

1. Elashoff J.D. nQuery Advisor Version 7.0 in 2007, Statistical Solutions, Cork.
2. Statistical and Power Analysis Software PASS, in, NCCS, http://www.ncss.com/pass.html.
3. East 5.3 A software for the design and interim monitoring of group-sequential clinical trials 2009, Cytel Software Corporation, Cambridge.
4. PEST, http://www.maths.lancs.ac.uk/department/research/statistics/mps/.
5. S+ SeqTrial, http://spotfire.tibco.com/Products/SPlus-SeqTrial.aspx.
6. Anderson K. gsDesign: Group Sequential Design-R Package Version 2.4-01 2011, http://CRAN.R-project.org/package=gsDesign.
7. Schoenfeld D.A. Sample-size formula for the proportional-hazards regression model. Biometrics 1983, 39:499-503.
8. Snapinn S., Jiang Q. Preservation of effect and the regulatory approval of new treatments on the basis of non-inferiority trials. Stat. Med. 2008, 27:382-391.
9. Hung H.M., Wang S.J., O'Neill R. Challenges and regulatory experiences with non-inferiority trial design without placebo arm. Biometrical J. Biometrische Zeitschrift 2009, 51:324-334.
10. FDA Guidance for Industry Non-Inferiority Clinical Trials 2010, http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM202140.pdf.
11. EMEA Committee for Medicinal Products for Human Use (CHMP) guideline on the choice of the non-inferiority margin. Stat. Med. 2006, 25:1628-1638.
12. Brown D., Volkers P., Day S. An introductory note to CHMP guidelines: choice of the non-inferiority margin and data monitoring committees. Stat. Med. 2006, 25:1623-1627.
13. D'Agostino R.B., Massaro J.M., Sullivan L.M. Non-inferiority trials: design concepts and issues-the encounters of academic consultants in statistics. Stat. Med. 2003, 22:169-186.
14. Ng T.H. Noninferiority hypotheses and choice of noninferiority margin. Stat. Med. 2008, 27:5392-5406.
15. Rothmann M., Li N., Chen G., Chi G.Y., Temple R., Tsou H.H. Design and analysis of non-inferiority mortality trials in oncology. Stat. Med. 2003, 22:239-264.
16. Freidlin B., Korn E.L., George S.L., Gray R. Randomized clinical trial design for assessing noninferiority when superiority is expected. J. Clin. Oncol. 2007, 25:5019-5023.
17. Kim K., Tsiatis A.A. Study duration for clinical trials with survival response and early stopping rule. Biometrics 1990, 46:81-92.
18. Jennison C., Turnbull B.W. Group Sequential Methods 1999, Chapman and Hall/CRC.
19. Pocock S.J. Interim analyses for randomized clinical trials: the group sequential approach. Biometrics 1982, 38:153-162.
20. O'Brien P.C., Fleming T.R. A multiple testing procedure for clinical trials. Biometrics 1979, 35:549-556.
21. DeMets D.L., Lan K.K. Interim analysis: the alpha spending function approach. Stat. Med. 1994, 13:1341-1352. discussion 1353-1356.
22. Freidlin B., Korn E.L. A comment on futility monitoring. Controlled Clin. Trials 2002, 23:355-366.
23. Freidlin B., Korn E.L. Monitoring for lack of benefit: a critical component of a randomized clinical trial. J. Clin. Oncol. 2009, 27:629-633.
24. Korn E.L., Freidlin B. Inefficacy interim monitoring procedures in randomized clinical trials: the need to report. Am. J. Bioethics 2011, 11:2-10.
25. Lachin J.M. A review of methods for futility stopping based on conditional power. Stat. Med. 2005, 24:2747-2764.
26. EMEA ICHE9: Note for guidance on statistical principles for clinical trials 1998, http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002928.pdf.
27. Whitehead J. The Design and Analysis of Sequential Clinical Trials 1997, John Wiley & Sons.
28. FDA Guidance for Clinical Trials Sponsor: Establishment and Operation of Clinical Trial Data Monitoring Committees 2006, http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm127073.pdf.
29. R Development Core Team R: A Language and Environment for Statistical Computing 2009, R Foundation for Statistical Computing, Vienna, Austria.
30. Lachin J.M., Foulkes M.A. Evaluation of sample size and power for analyses of survival with allowance for nonuniform patient entry, losses to follow-up, noncompliance, and stratification. Biometrics 1986, 42:507-519.
31. Seshan V.E. clinfun: Clinical Trial Design and Data Analysis Functions-R package version 0. 9. 7 2011, http://cran.r-project.org/web/packages/clinfun.
32. Anisimov V.V., Fedorov V.V. Modelling, prediction and adaptive adjustment of recruitment in multicentre trials. Stat. Med. 2007, 26:4958-4975.
33. Barthel F.M, Babiker A., Royston P., Parmar M.K. Evaluation of sample size and power for multi-arm survival trials allowing for non-uniform accrual, non-proportional hazards, loss to follow-up and cross-over. Stat. Med. 2006, 25:2521-2542.
34. Casper C., Perez O.A. ldbounds: Lan-DeMets Method for Group Sequential Boundaries-R package version 1.0-1 2006, http://cran.r-project.org/web/packages/ldbounds.
35. Izmirlian G. PwrGSD: Power in a Group Sequential Design-R package version 1.16 2010, http://CRAN.R-project.org/packages/PwrGSD.